KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Raw Materials (2021 - 2025)

Rigel Pharmaceuticals (RIGL) has 5 years of Raw Materials data on record, last reported at $7.0 million in Q3 2025.

  • For Q3 2025, Raw Materials rose 342.96% year-over-year to $7.0 million; the TTM value through Sep 2025 reached $7.0 million, up 342.96%, while the annual FY2024 figure was $1.1 million, 76.63% down from the prior year.
  • Raw Materials reached $7.0 million in Q3 2025 per RIGL's latest filing, down from $9.6 million in the prior quarter.
  • Across five years, Raw Materials topped out at $9.6 million in Q2 2025 and bottomed at $1.1 million in Q4 2024.
  • Average Raw Materials over 5 years is $4.6 million, with a median of $4.6 million recorded in 2022.
  • Peak YoY movement for Raw Materials: plummeted 76.63% in 2024, then surged 348.76% in 2025.
  • A 5-year view of Raw Materials shows it stood at $5.1 million in 2021, then fell by 11.42% to $4.6 million in 2022, then rose by 1.19% to $4.6 million in 2023, then tumbled by 76.63% to $1.1 million in 2024, then surged by 545.31% to $7.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Raw Materials were $7.0 million in Q3 2025, $9.6 million in Q2 2025, and $1.1 million in Q1 2025.